Data Engineer, Valo Health
Translational Data Science
$125-170k
Platform for drug development & discovery
Job no longer available
Platform for drug development & discovery
201-500 employees
Job no longer available
$125-170k
201-500 employees
Company mission
To make the drug discovery and development process faster, less expensive, and with a higher probability of success.
Role
Who you are
- Bachelor’s + 2 years of experience or recent Master’s degree in computer science, information systems, computational sciences (e.g. bioinformatics, computational biology, epidemiology), or related fields
- Familiarity with various clinical data types (e.g., EHR/EMR, clinical trials, claims)
- Familiarity with any medical coding systems is a plus, (e.g. ICD9/10, CPT, ATC, LOINC, SNOMED, UMLS)
- Must have experience in Python and SQL (e.g. PostgreSQL, MySQL, etc.)
- Familiarity with releases/versioning of datasets for internal users
- Familiarity with data processing workflows, data platforms (e.g., spark, snowflake) , and cloud environments (e.g., AWS, GCP)
- Experience with data and software engineering best practices and testing methodologies (data provenance, collaborative development using source control management (git, bitbucket), code versioning, reproducibility, etc.)
What the job involves
- You will be part of the data engineering core in the Translational Data Sciences group, working with data engineers and data scientists building powerful computational tools and answering critical scientific questions about patients, diseases, and drug development
- In this role, you will contribute to Valo’s EHR data engineering capabilities, transforming structured and unstructured data from proprietary sources into analysis-ready data products for internal teams
- To do so you will work closely with data engineers and data scientists supporting epidemiology, patient clustering, and biomarker identification
- Work on a team developing data transformation pipelines and systems to ingest and harmonize data in Valo’s data ecosystems
- Contribute to the data source backend for our epidemiology and patient machine learning
- Build visualization and data extraction tools
- Work using agile development techniques
- Learn to provide high quality data through unit tests, validation tests, code reviews
- Be a dynamic and active team member
Our take
Drug development is a critical component of health care. Reducing costs, improving discovery processes, and accelerating drug development are all critical to success in the drug pipeline. Using human-centric data and ML-anchored computation, Valo Health’s integrated drug development platform, known as Opal, improves outcomes in drug development, by leveraging advanced data analysis.
Drug development entails a variety of steps including molecule discovery, clinical development, and target discovery. With the vast amount of data that is generated, a system like Opal incentivizes investment in outcomes that are more likely to correspond with effective treatments. This reduces the number and expense of clinical trials needed to demonstrate drug effectiveness.
There are a variety of competitors in the data-driven drug discovery field, but this vast market should still offer enough space for Valo Health to grow. Back in 2021, the company had a set-back in the surprise calling off of a merger that would have seen it go public, but despite this has continued to operate well and advance towards its goal of transforming the drug development process.
Freddie
Company Specialist at Welcome to the Jungle
Insights
-23% employee growth in 12 months
Company
Funding (last 2 of 7 rounds)
Nov 2021
$1m
LATE VC
Jul 2021
$33.5m
LATE VC
Total funding: $487.5m
Company benefits
- Medical, Dental, and Vision Insurance
- Flexible Time-off
- 401K
- Corporate Engagement Opportunities with Local Non-Profit Organizations
- Commuter Reimbursement
- Fitness Reimbursement
- Pet Insurance
Company HQ
Back Bay East, Boston, MA
Leadership
Brian Alexander
(CEO)Also a Partner at Flagship Pioneering. Previously SVP of Genentech, CEO of Foundation Medicine and was a n Associate Professor at Harvard Medical School.
Brett Blackman
(COO)Member of the Board of Directors at Stanley Manne Children's Research Institute. Previously Interim Chief Scientific Officer at Omega Therapeutics and was a Strategic R&D Advisor at Ohana Biosciences, Inc.
Share this job